Source:

Press Release

Disclosures: Vaughan is employed by Cognito Therapeutics.
March 11, 2022
1 min read
Save

Cognito Therapeutics, Aetion to partner on AI model that identifies AD patients

Source:

Press Release

Disclosures: Vaughan is employed by Cognito Therapeutics.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Neurotechnology company Cognito Therapeutics announced a partnership with Aetion to develop a validated predictive model that will help identify patients with rapidly progressing mild cognitive impairment and Alzheimer’s disease.

The artificial intelligence model, built on roughly 5 million commercial and Medicare claims, will enable population-level risk and cost assessments for payers and integrated health systems, clinical study population, enrichment and, once it becomes available, will support deployment of Cognito's intervention to AD patients with the highest risk for rapid disease progression.

Man trying to think
Source: Adobe Stock

“Aetion is a leader in turning real-world data into [real-world evidence] to inform critical decision-making across product development, reimbursement and commercialization,” Brent Vaughan, CEO of Cognito Therapeutics, said a press release. “Our partnership with Aetion to develop an innovative model will accelerate our late-stage clinical programs and bring our therapy to the millions of patients living with [mild cognitive impairment] and Alzheimer’s disease, where safer options are still needed.”